CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
CStone’s executive reshuffle comes after company discovers questionable investment made by finance vice president in 2021 Key Takeaways: CStone brought four products to market last year, and its losses have…
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
FAST NEWS: JPMorgan boosts WuXi AppTec stake
2359.HK 603259.SHG
-
FAST NEWS: U.S. investment firm boosts WuXi AppTec stake
2359.HK 603259.SHG
Discover hidden China stock gems in our weekly newsletter